Beta-blocker use and 30-day all-cause readmission in medicare beneficiaries with systolic heart failure

Vikas Bhatia, Navkaranbir S. Bajaj, Kumar Sanam, Taimoor Hashim, Charity J. Morgan, Sumanth D. Prabhu, Gregg C. Fonarow, Prakash Deedwania, Javed Butler, Peter Carson, Thomas E. Love, Raya Kheirbek, Wilbert S. Aronow, Stefan D. Anker, Finn Waagstein, Ross Fletcher, Richard M. Allman, Ali Ahmed

Research output: Contribution to journalArticle

Abstract

Background Beta-blockers improve outcomes in patients with systolic heart failure. However, it is unknown whether their initial negative inotropic effect may increase 30-day all-cause readmission, a target outcome for Medicare cost reduction and financial penalty for hospitals under the Affordable Care Act. Methods Of the 3067 Medicare beneficiaries discharged alive from 106 Alabama hospitals (1998-2001) with a primary discharge diagnosis of heart failure and ejection fraction

Original languageEnglish
Pages (from-to)715-721
Number of pages7
JournalAmerican Journal of Medicine
Volume128
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

Keywords

  • Beta-blockers
  • Hospitalization
  • Older adults
  • Readmission
  • Systolic heart failure

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Beta-blocker use and 30-day all-cause readmission in medicare beneficiaries with systolic heart failure'. Together they form a unique fingerprint.

  • Cite this

    Bhatia, V., Bajaj, N. S., Sanam, K., Hashim, T., Morgan, C. J., Prabhu, S. D., Fonarow, G. C., Deedwania, P., Butler, J., Carson, P., Love, T. E., Kheirbek, R., Aronow, W. S., Anker, S. D., Waagstein, F., Fletcher, R., Allman, R. M., & Ahmed, A. (2015). Beta-blocker use and 30-day all-cause readmission in medicare beneficiaries with systolic heart failure. American Journal of Medicine, 128(7), 715-721. https://doi.org/10.1016/j.amjmed.2014.11.036